Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Synergy Pharmaceuticals nets $122mm via follow-on

Executive Summary

Synergy Pharmaceuticals Inc. (gastrointestinal disease therapeutics) netted $122mm through the follow-on public offering of 20.3mm common shares at $6.15. The company will use the proceeds to help fund commercial activities for its chronic idiopathic constipation drug Trulance, and for ongoing Phase III trials of plecanatide for irritable bowel syndrome with constipation.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies